HUM Stock Recent News

While the top- and bottom-line numbers for Humana (HUM) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

SAN DIEGO , Feb. 11, 2025 /PRNewswire/ -- The Shareholders Foundation, Inc. announced an update in the lawsuit that is pending for certain investors in shares of Humana Inc. (NYSE: HUM). Investors who purchased shares of Humana Inc. (NYSE: HUM) prior to July 2022 and continue to hold any of those NYSE: HUM shares have also certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

Humana (HUM) came out with a quarterly loss of $2.16 per share versus the Zacks Consensus Estimate of a loss of $2.26. This compares to loss of $0.11 per share a year ago.

Humana Tuesday reported $1.2 billion in 2024 profits that included a $693 million fourth quarter loss as the health insurer exits unprofitable Medicare Advantage markets for 2025.

Humana forecast annual profit slightly below Wall Street estimates on Tuesday, signaling that costs from its government-backed plans for older Americans would remain elevated for the rest of the year.

LOUISVILLE, Ky.--(BUSINESS WIRE)--Humana Inc. (NYSE: HUM) today reported consolidated pretax results and net (loss) earnings per share for the quarter ended December 31, 2024 (4Q24) versus the quarter ended December 31, 2023 (4Q23) and for the year ended December 31, 2024 (FY 2024) versus the year ended December 31, 2023 (FY 2023) as noted in the tables below. Consolidated (loss) income before income taxes and equity in net losses (pretax results) In millions 4Q24 (a) 4Q23 (a) FY 2024 (a) FY 20.

Health insurance company Humana HUM is set to release its fourth-quarter 2024 earnings report on Feb. 11, before market hours. The stock has dropped 2.37% from the previous close, as of writing, on Feb.10, according to Benzinga Pro.

HUM's Q4 results are likely to suffer a blow due to escalating operating costs, partly offset by membership growth in the Individual and Group Medicare Advantage business lines.

Besides Wall Street's top -and-bottom-line estimates for Humana (HUM), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2024.

With its groundbreaking AI Care platform fueling rapid growth, Sword is transforming healthcare through AI. The addition of Bruce Broussard as Board Advisor will be instrumental in enhancing industry expertise and shaping the company's future. With its groundbreaking AI Care platform fueling rapid growth, Sword is transforming healthcare through AI. The addition of Bruce Broussard as Board Advisor will be instrumental in enhancing industry expertise and shaping the company's future.